That scenario could be possible. Another possible scenario for the briefing document is a favorable clinical review from the urologist/reviewer, but a questionable review from the biostatistician.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.